Lovenox Should NOT Be Injected in the Arm
The FDA-approved administration technique for enoxaparin (Lovenox) specifies subcutaneous injection into the abdominal wall only, alternating between the left and right anterolateral and posterolateral sites 1. The arm is not an approved injection site.
Why the Abdomen is the Standard Site
The FDA drug label explicitly states: "Administration should be alternated between the left and right anterolateral and left and right posterolateral abdominal wall" 1. This is the only approved subcutaneous injection site for enoxaparin, based on the pharmacokinetic and safety data submitted for FDA approval.
Evidence Against Arm Administration
While one study examined arm versus abdominal injection in critically ill patients, the findings actually support avoiding the arm 2:
- Larger hematomas occurred with arm injection: After 72 hours, the median hematoma area was significantly larger with arm injection (20 mm² vs 2 mm², P=0.027) 2
- The abdomen demonstrated a better safety profile with smaller hematomas
- Though ecchymosis rates were similar between sites, the clinically meaningful outcome (hematoma size) favored abdominal administration
Proper Injection Technique
Follow this specific technique for abdominal injection 1:
- Patient positioning: Patient should be lying down
- Site selection: Alternate between four quadrants of the abdominal wall (left/right anterolateral and left/right posterolateral)
- Injection method:
- Create a skin fold between thumb and forefinger
- Insert the entire needle length into the skin fold
- Hold the skin fold throughout the injection
- Do NOT expel the air bubble from prefilled syringes (30 mg and 40 mg doses)
- Post-injection: Do NOT rub the injection site to minimize bruising
Clinical Implications
The restriction to abdominal injection is not arbitrary—it reflects:
- Optimal subcutaneous absorption characteristics
- Predictable pharmacokinetics validated in clinical trials
- Minimized local complications (particularly hematoma formation)
- All dosing recommendations in major guidelines assume abdominal administration 3, 4, 3, 4
Common pitfall: Patients or providers may consider arm injection for convenience or patient preference, but this deviates from FDA-approved administration and may increase the risk of local complications, particularly hematoma formation that could be clinically significant in anticoagulated patients.
If a patient has contraindications to abdominal injection (e.g., recent abdominal surgery, abdominal wall infection, extensive abdominal scarring), consult with the prescribing physician about alternative anticoagulation strategies rather than using an unapproved injection site.